• Iovance Biotherapeutics Inc IOVA.OQ reported a quarterly adjusted loss of 36 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -42 cents. The mean expectation of eleven analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -27 cents to -21 cents per share.

• Revenue rose 6,798.5% to $49.32 million from a year ago; analysts expected $81.70 million.

• Iovance Biotherapeutics Inc's reported EPS for the quarter was a loss of 36 cents​.

• The company reported a quarterly loss of $116.16 million.

• Iovance Biotherapeutics Inc shares had fallen by 6.0% this quarter and lost 57.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Iovance Biotherapeutics Inc is $18.00

This summary was machine generated from LSEG data May 8 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)